Tale of the Tape 

Hiya folks. Welcome back to the market of stocks!

Nifty and Sensex fell -0.3% each, following weak global cues after Moody’s downgraded the US’s credit rating. Midcaps were flat, while Smallcaps (+0.5%) posted decent gains. The advance-decline ratio was in favour of the bulls (3:2). Here’s the Nifty500 heatmap:

Most sectors ended in the green. Real Estate (+2.3%) and PSU Banks (+1.5%) saw the most buying. IT (-1.3%) witnessed the most selling pressure.

Protean eGov (-20%) got KO-ed after missing out on a big GOI contract. Meanwhile, Vodafone-Idea (-8%) nosedived too after failing to secure SC relief. More details below.

Divi’s Labs (+5%) had a solid Q4 show. Delhivery (+10%) put up a full year of profitability. Check out their results below.

Graphite India, Banco Products and Zen Technologies saw big moves. Take a look at their charts below to find out why.

Bajaj Auto (+4%) was the top Nifty gainer, outperforming a weaker market.

NCC was up +4% after CLSA reiterated its bullish call; the brokerage sees a +34% upside and advises to buy on dips.

Container Corporation of India (+2%) will consider a bonus share proposal on May 22.

Q4 reactions. CreditAccess Grameen cracked -7% after its Q4 profit nosedived -88% YoY.  Meanwhile, Data Patterns had a great Q4, but the stock was down -2% due to profit-booking.

Earnings
Earnings Roundup

Divi's Laboratories (+6%) Q4 results beat Street estimates! Its key API vertical grew +13% YoY helping boost the topline. FYI - this wraps up a strong H2FY25 for APIs after nearly eight quarters of underperformance. 

The company did face pricing pressure in its generics portfolio. But stable raw material prices & richer product mix helped bump up margins and lift the bottomline! Finally, the cherry on top: Divi’s confirmed its double-digit growth forecast for FY26 and said key growth triggers include its obesity drug biz. Nuvama -- which hiked its target price to  Rs 7,225 p/sh vs Rs 6,830 p/sh earlier -- believes oral obesity drugs could generate up to $175 million in revenue.

Here are its key stats:

• Revenue: Rs 2,585 cr; +12% YoY (vs Est: Rs 2,564 cr)

• EBITDA: Rs 886 cr; +21% YoY (vs Est: Rs 818 cr)

• EBITDA Margin: 34.27% vs 31.74% YoY (vs Est: 31.9%)

• PAT: Rs 662 cr; +23% YoY (vs Est: Rs 608 cr)

Divi's Laboratories is up +9% YTD.

Delhivery (+10%) soared after posting a turnaround Q4. The company swung back into profits for both the quarter and FY25.  Fun fact: this makes it the first-ever full year of profitability for the firm!

FYI - Q4 growth in its core express parcel biz remained weak, with revenue just up +3% YoY. What really shined was its ‘partial truckload’ (PTL) vertical, with volumes growing +19% YoY. The PTL segment’s margins in Q4 also jumped to 10.8% vs 2.2% YoY. This helped prop up overall profitability for Delhivery.

Here is its Q4 report card:

• Revenue: Rs 2,192 cr; +6% YoY

• EBITDA: Rs 119 cr; +3x YoY

• EBITDA Margins: 5.4% vs 2.2% YoY

• PAT: Rs 73 cr vs Rs 69 cr loss last year

Delhivery is +1% YTD.

Specials
5 Stocks Under Rs 500 - By SEBI RAs

As markets recover, which stocks should be on your radar? Check out the top Mid and Small Cap stocks under ₹500 with massive upside potential, as shared by SEBI RAs on Stocktwits.